Search

Displaying results 4611 - 4620 of 10000 in total
  1. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  2. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain). … NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin.

  3. Drug

    Aminacrine

    go.drugbank.com/drugs/DB11561
    Investigational

    A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Rufloxacin

    go.drugbank.com/drugs/DB13772
    Investigational

    Rufloxacin is a quinolone antibiotic.[A31894]

    Categories: Topoisomerase II Inhibitors
  5. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  6. Drug

    Cefpirome

    go.drugbank.com/drugs/DB13682
    Approved

    Cefpirome is a β-lactam or cephalosporin.[A249055]

  7. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  8. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  9. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been

    Synonyms: Cyclo(-L-glycyl-L-2-allylproline), Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-
  10. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim.